Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monika Žurková

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Vnitrni Lekarstvi|January 6, 2018
[Sarcoidosis - enigmatic disease still unresolved]Vítězslav Kolek, Monika Žurková, Vladimíra Lošťáková
Casopis Lekaru Ceskych|April 16, 2020
Drug induced lung toxicity by nitrofurantoinSamuel Genzor, Vítězslav Kolek, Monika Žurková, et al.
Vnitrni Lekarstvi|January 6, 2018
[The complications after lung transplantation]Petr Jakubec, Monika Žurková, Lenka Hajdová, et al.
Respiratory Medicine|September 10, 2024
Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based studyMartina Koziar Vašáková, Jakub Gregor, Nesrin Mogulkoc, et al.
Archivos De Bronconeumologia|December 30, 2023
The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE RegistryJakub Gregor, Yochai Adir, Martina Šterclová, et al.
Casopis Lekaru Ceskych|August 3, 2016
[Idiopathic pulmonary fibrosis prognostic factors - analysis of the Czech registry]Martina Doubková, Michal Uher, Vladimír Bartoš, et al.
BMC Pulmonary Medicine|May 3, 2023
The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registryMarianna Štefániková, Martina Doubková, Petra Ovesná, et al.
The Clinical Respiratory Journal|September 2, 2017
EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosisMartina Doubková, Jan Švancara, Michal Svoboda, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Vnitrni Lekarstvi|January 6, 2018
[Sarcoidosis - enigmatic disease still unresolved]Vítězslav Kolek, Monika Žurková, Vladimíra Lošťáková
Casopis Lekaru Ceskych|April 16, 2020
Drug induced lung toxicity by nitrofurantoinSamuel Genzor, Vítězslav Kolek, Monika Žurková, et al.
Vnitrni Lekarstvi|January 6, 2018
[The complications after lung transplantation]Petr Jakubec, Monika Žurková, Lenka Hajdová, et al.
Respiratory Medicine|September 10, 2024
Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based studyMartina Koziar Vašáková, Jakub Gregor, Nesrin Mogulkoc, et al.
Archivos De Bronconeumologia|December 30, 2023
The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE RegistryJakub Gregor, Yochai Adir, Martina Šterclová, et al.
Casopis Lekaru Ceskych|August 3, 2016
[Idiopathic pulmonary fibrosis prognostic factors - analysis of the Czech registry]Martina Doubková, Michal Uher, Vladimír Bartoš, et al.
BMC Pulmonary Medicine|May 3, 2023
The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registryMarianna Štefániková, Martina Doubková, Petra Ovesná, et al.
The Clinical Respiratory Journal|September 2, 2017
EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosisMartina Doubková, Jan Švancara, Michal Svoboda, et al.
Pageof 1